Literature summary for 5.6.2.2 extracted from

Rhee, H.K.; Park, H.J.; Lee, S.K.; Lee, C.O.; Choo, H.Y.
Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones (2007), Bioorg. Med. Chem., 15, 1651-1658.

Search for more literature for 5.6.2.2

Inhibitors

Inhibitors	Comment	Organism	Structure
2-chloro-3-[2-(dimethylamino)isopropoxy]benzo-[b]naphtho[2,3-d]furan-6,11-dione	0.05 mM, 88% inhibition. Comparison of cytotoxicity against various human cancer cells	Homo sapiens
3-[2-(diethylamino)ethoxy]benzo[b]naphtho[2,3-d]-furan-6,11-dione	0.05 mM, 91% inhibition. Comparison of cytotoxicity against various human cancer cells	Homo sapiens
3-[2-(dimethylamino)isopropoxy]benzo[b]naphtho[2,3-d]furan-6,11-dione	0.05 mM, 84% inhibition. Comparison of cytotoxicity against various human cancer cells	Homo sapiens
3-[2-(dimethylamino)propoxy]benzo[b]naphtho[2,3-d]furan-6,11-dione	0.05 mM, 100% inhibition. Comparison of cytotoxicity against various human cancer cells	Homo sapiens
8-(2-(diethylamino)ethoxy)benzofuro[3,2-g]quinoline-5,11-dione	0.05 mM, 100% inhibition. Comparison of cytotoxicity against various human cancer cells	Homo sapiens
doxorubicin	0.05 mM, 100% inhibition	Homo sapiens
etoposide	0.05 mM, 100% inhibition	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	recombinant topoisomerase II	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
A-549 cell	-	Homo sapiens	-
HCT-116 cell	-	Homo sapiens	-
HL-60 cell	-	Homo sapiens	-
HT-1080 cell	-	Homo sapiens	-
SK-MEL-2 cell	-	Homo sapiens	-
SK-OV-3 cell	-	Homo sapiens	-
SNU-638 cell	-	Homo sapiens	-
XF-498 cell	-	Homo sapiens	-

IC50 Value

IC50 Value	IC50 Value Maximum	Comment	Organism	Inhibitor	Structure
0.00068	-	-	Homo sapiens	8-(2-(diethylamino)ethoxy)benzofuro[3,2-g]quinoline-5,11-dione
0.00119	-	-	Homo sapiens	3-[2-(dimethylamino)propoxy]benzo[b]naphtho[2,3-d]furan-6,11-dione
0.0784	-	-	Homo sapiens	etoposide

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)